Vaxcell Competitors

Stocks . Korea . 
Stock . Vaxcell Bio Therapeutics Co
323990 Stock  KRW 12,810  390.00  2.95%   
Vaxcell Bio Therapeu competes with Hyundai Home, Sangsangin Investment, Hanwha InvestmentSecuri, Atinum Investment, and SV Investment; as well as few others. Analyzing Vaxcell Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Vaxcell Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Vaxcell Bio Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Vaxcell Bio competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
12,80812,81012,812
Details
Intrinsic
Valuation
LowRealHigh
10,93310,93514,091
Details
Naive
Forecast
LowNextHigh
13,45413,45613,458
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
11,41012,45513,500
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vaxcell Bio. Your research has to be compared to or analyzed against Vaxcell Bio's peers to derive any actionable benefits. When done correctly, Vaxcell Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Vaxcell Bio Therapeu.

Vaxcell Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Vaxcell Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Vaxcell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Vaxcell Bio Therapeu does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
078020
+ 0.94
289080
078020
+ 0.94
118000
118000
+ 0.9
289080
289080
+ 0.89
001290
289080
+ 0.8
057050
078020
+ 0.78
057050
  
High negative correlations   
289080
- 0.74
003535
003535
- 0.72
001290
003535
- 0.72
057050
078020
- 0.64
003535
118000
- 0.64
003535
118000
- 0.22
021080

Risk-Adjusted Indicators

There is a big difference between Vaxcell Stock performing well and Vaxcell Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vaxcell Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Vaxcell Bio Competitive Analysis

The better you understand Vaxcell Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Vaxcell Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Vaxcell Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
323990 057050 001290 003535 021080 289080 118000 078020
 2.95 
 12,810 
Vaxcell
 0.33 
 45,150 
Hyundai
 1.58 
 436.00 
Sangsangin
 0.71 
 7,120 
Hanwha
 1.46 
 2,355 
Atinum
 4.85 
 1,354 
289080
 1.59 
 310.00 
Chorokbaem
 3.54 
 3,955 
EBEST
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
Low
Low
Low
Low
Below Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Sell
Strong Sell
Cautious Hold
Current Ratio
N/A
N/A
N/A
N/A
12.84 X
2.45 X
N/A
2.45 X
Net Asset
31.28 B
N/A
582.48 B
11.79 T
198.8 B
78.61 B
176.3 B
6.93 T
Profit Margin
N/A
N/A
0.03 %
0.03 %
0.35 %
0.30 %
(1.60) %
0.10 %
EBITDA
(4.06 B)
N/A
N/A
N/A
N/A
N/A
16.64 B
N/A
Current Valuation
1.06 T
N/A
259.04 B
2.43 T
193.94 B
212.77 B
72.69 B
(813.51 B)
Operating Margin
N/A
N/A
0.19 %
0.28 %
0.39 %
0.44 %
(0.03) %
0.41 %
Price To Book
N/A
N/A
0.37 X
0.72 X
N/A
N/A
0.47 X
N/A
Retained Earnings
N/A
N/A
N/A
N/A
17.39 B
N/A
N/A
184.12 B
Current Asset
N/A
N/A
N/A
N/A
7.88 B
N/A
N/A
3.52 T
Beta
N/A
N/A
0.75
1.6
2.02
-1.18
1.64
0.84
Number Of Employees
N/A
N/A
2
1.03 K
17
15
23
20
Shares Outstanding
N/A
N/A
106.26 M
4.2 M
48 M
53.23 M
84.7 M
51.06 M
Cash Flow From Operations
(4.66 B)
N/A
(84.74 B)
(1.11 T)
33.71 B
(4.52 B)
(1.49 B)
(171.23 B)
Annual Yield
N/A
N/A
N/A
0.05 %
0.03 %
N/A
N/A
0.08 %
Total Debt
37.39 M
N/A
N/A
N/A
1.47 B
505.93 M
N/A
1.23 T
Return On Equity
-21.18
N/A
0.006
0.0347
57.28
16.5
-0.24
7.5
Z Score
N/A
N/A
N/A
N/A
57.0
N/A
N/A
N/A
Return On Asset
N/A
N/A
0.0022
0.0046
0.074
0.13
-0.0023
0.0236
Current Liabilities
N/A
N/A
N/A
N/A
613 M
N/A
N/A
1.26 T
Total Asset
31.28 B
N/A
582.48 B
11.79 T
198.8 B
78.61 B
176.3 B
6.93 T
Last Dividend Paid
N/A
N/A
N/A
250.0
N/A
N/A
N/A
N/A
Debt To Equity
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.48 %
Shares Owned By Institutions
3.92 %
N/A
0.01 %
7.60 %
34.71 %
0.56 %
0.14 %
62.92 %
Market Capitalization
554.12 B
N/A
90.96 B
688.61 B
140.16 B
133.09 B
48.45 B
256.81 B
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7.06 X
Price To Sales
N/A
N/A
2.16 X
0.30 X
14.66 X
5.43 X
2.98 X
0.17 X
Net Income
(4.76 B)
N/A
8.97 B
144.11 B
66 B
10.71 B
7.74 B
160.83 B
Shares Owned By Insiders
13.55 %
N/A
66.27 %
N/A
N/A
27.20 %
38.61 %
2.10 %
Revenue
N/A
N/A
40.53 B
508.78 B
117.62 B
31.5 B
18.61 B
1.24 T
Working Capital
N/A
N/A
N/A
N/A
7.26 B
N/A
N/A
2.26 T
Cash And Equivalents
27.31 B
N/A
N/A
N/A
50.26 B
7.32 B
N/A
34.63 B
Cash Per Share
N/A
N/A
N/A
N/A
164.09 X
145.62 X
N/A
N/A
Gross Profit
(5.39 M)
N/A
41.55 B
1.7 T
23.81 B
27.56 B
5.06 B
1.89 T
Day Typical Price
12733.33
45116.67
441.0
7113.33
2368.33
1364.0
309.67
4011.67
Accumulation Distribution
0.0241
224.19
5158.44
353.68
4564.12
36710.69
11427.58
2307.51
Market Facilitation Index
310.0
0.0627
2.0E-4
0.0127
7.0E-4
2.0E-4
1.0E-4
0.003
Daily Balance Of Power
(1.26)
(0.19)
(0.37)
0.2778
(0.39)
(0.62)
(0.29)
(0.85)
Period Momentum Indicator
(390.00)
(150.00)
(7.00)
50.0
(35.00)
(69.00)
(5.00)
(145.00)
Rate Of Daily Change
0.97
1.0
0.98
1.01
0.99
0.95
0.98
0.96
Day Median Price
12695.0
45100.0
443.5
7110.0
2375.0
1369.0
309.5
4040.0
Price Action Indicator
(80.00)
(25.00)
(11.00)
35.0
(37.50)
(49.50)
(2.00)
(157.50)
Relative Strength Index
23.99
27.66
36.37
75.24
66.98
36.9
47.55
40.79
Coefficient Of Variation
(696.47)
(1,373)
(850.04)
1929.56
(3,817)
(410.61)
(351.84)
(397.10)
Mean Deviation
1.65
0.8543
0.9932
2.94
1.67
1.23
1.13
0.9696
Jensen Alpha
(0.34)
(0.08)
(0.19)
0.0153
(0.12)
(0.50)
(0.46)
(0.37)
Total Risk Alpha
(0.67)
(0.29)
(0.42)
(0.53)
(0.46)
(0.77)
(0.72)
(0.56)
Sortino Ratio
N/A
N/A
N/A
0.0304
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
10.53
N/A
N/A
N/A
N/A
Standard Deviation
2.12
1.16
1.44
4.56
2.33
1.85
1.57
1.31
Kurtosis
(0.13)
0.7661
2.82
6.88
1.82
3.86
3.58
0.9106
Potential Upside
3.53
1.82
2.0
6.53
4.0
1.98
1.69
1.84
Treynor Ratio
(1.64)
0.6959
(2.64)
0.1369
(0.17)
(1.51)
(7.11)
(1.52)
Maximum Drawdown
9.03
6.0
8.73
33.31
13.09
12.35
8.63
7.02
Variance
4.48
1.35
2.08
20.76
5.42
3.42
2.47
1.71
Market Risk Adjusted Performance
(1.63)
0.7059
(2.63)
0.1469
(0.16)
(1.50)
(7.10)
(1.51)
Risk Adjusted Performance
(0.10)
(0.05)
(0.09)
0.0479
(0.01)
(0.18)
(0.21)
(0.19)
Skewness
(0.21)
0.2625
0.6746
1.61
0.6969
(0.86)
(0.71)
(0.37)
Semi Deviation
N/A
N/A
N/A
3.01
N/A
N/A
N/A
N/A
Information Ratio
(0.21)
(0.19)
(0.21)
0.0216
(0.09)
(0.32)
(0.37)
(0.36)
Value At Risk
(4.32)
(1.87)
(2.32)
(4.23)
(2.90)
(3.71)
(2.49)
(2.54)
Expected Short fall
N/A
N/A
N/A
(4.11)
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
3.24
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
9.03
N/A
N/A
N/A
N/A

Vaxcell Bio Competition Performance Charts

Five steps to successful analysis of Vaxcell Bio Competition

Vaxcell Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Vaxcell Bio Therapeu in relation to its competition. Vaxcell Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Vaxcell Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Vaxcell Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Vaxcell Bio Therapeu, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Vaxcell Bio position

In addition to having Vaxcell Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate ETFs Thematic Idea Now

Corporate ETFs
Corporate ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 222 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Vaxcell Stock

Vaxcell Bio financial ratios help investors to determine whether Vaxcell Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vaxcell with respect to the benefits of owning Vaxcell Bio security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY